The negative study result for the drug, called SAGE-324, is a significant setback for Sage’s neurology pipeline, and its effort to develop a successful medicine beyond Zurzuvae, ...

Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer.

SAGE-324 was one of two Sage drugs licensed by Biogen in 2020 in a $3 billion deal – including more than $1.5 billion upfront – that also gave it rights to zuranolone for psychiatric disorders ...

Biogen and Sage Therapeutics are discontinuing further development of their drug Zurzuvae as a potential treatment for major depressive disorder, a move that follows last year’s FDA rejection of ...

Sage Therapeutics Inc. plunged after a mid-stage study of its drug to treat essential tremor failed, the second setback for its pipeline in three months. The medicine didn’t significantly reduce ...

When Sage Therapeutics and Biogen applied for FDA approval of zuranolone, they submitted an application for the drug to treat not only postpartum depression but also major depressive disorder in ...

The experts agreed that carnosic acid could potentially improve the inflammation that generally occurs in most aging brains. There are cautions however.

Sage already sells a drug, Zulresso, for postpartum depression. However, it’s given as a continuous intravenous infusion over 60 hours, and carries an FDA warning for excessive sleepiness and ...